Company: SCLXW
Filing Date: 2025-01-21
Form Type: 424B3
Source: 0000950170-25-007387
Chunk: 5

Company: Scilex Holding Co
Filing Date: 2025-01-21
Form: 424B3
Chunk 5
---
2, respectively, and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

| Exhibit Number 
 99.1           
 99.2           | Description                                                                                           
 Press Release issued by Scilex Holding Company on January 21, 2025.                                   
 Press Release issued by Scilex Holding Company on January 21, 2025.                                   |
|:---------------|:------------------------------------------------------------------------------------------------------|
| 104            | Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL). |

<div align='center'>2

SIGNATURES</div>

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

|                        | SCILEX HOLDING COMPANY |                                       |
|                        | By:                    | /s/ Jaisim Shah                       |
|                        | Name:                  | Jaisim Shah                           |
| Date: January 21, 2025 | Title:                 | Chief Executive Officer and President |

<div align='center'>3</div>

Exhibit 99.1

FOR IMMEDIATE RELEASE

January 21, 2025

Scilex Holding Company Announces Filing of its Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2024

PALO ALTO, CALIFORNIA – January 21, 2025 (GLOBE NEWSWIRE) -Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and, following the formation of its proposed joint venture with IPMC Company, neurodegenerative and cardiometabolic disease, today announced that it has filed its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 and expects to receive notification from The Nasdaq Stock Market LLC that it has regained compliance with Nasdaq Listing Rule 5250(c)(1).

For more information on Scilex Holding Company, refer towww.scilexholding.com

For more information on Semnur Pharmaceuticals, Inc., refer towww.semnurpharma.com

For more information on Scilex Holding Company Sustainability Report, refer towww.scilexholding.com/investors